Transdermal Delivery

Passive diffusion occurs when drug molecules move from the formulation in contact with the skin across the outer stratum corneum and into deeper tissues or the bloodstream. The process does not rely on an externally assisted transport mechanism. Its effectiveness therefore depends on whether the drug and formulation support movement through this skin barrier.

Drug properties, formulation design, skin condition, and the delivery system all influence how much compound crosses the skin and where it acts. These variables can affect both the rate and consistency of delivery. Clinical evaluation must therefore consider the intended local or systemic effect rather than treating every skin application as equivalent.

Passive diffusion uses the concentration relationship between the formulation and the skin, whereas assisted transport adds a delivery design that helps move molecules across the stratum corneum. This distinction matters when the skin barrier limits movement. Choosing between the two approaches depends on the compound, formulation, skin conditions, and desired clinical outcome.

A clinical workflow begins by selecting a suitable therapeutic compound and delivery design for the intended local or systemic effect. The system is then placed in contact with the skin so the drug can cross the stratum corneum. Assessment should account for skin condition and treatment goals, because these factors influence delivery performance and consistency.

Clinicians may consider this approach when controlled, sustained dosing, reduced gastrointestinal exposure, or avoidance of first-pass metabolism is clinically relevant. It can also support patient-centered care during longer-term treatment. The choice still depends on drug properties, formulation, skin condition, and delivery design, so transdermal administration is an alternative rather than a universal replacement.

Depending on the delivery system and treatment design, transdermal administration can produce effects in underlying tissues or throughout the body. Local delivery targets tissues near the application site, while systemic delivery depends on entry into the bloodstream. Controlled, sustained dosing may help align drug exposure with longer-term clinical goals and patient needs.